Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57049
A TRAVELING SARS-COV-2 LABORATORY AS PART OF A PANDEMIC RESPONSE AMONG VULNERABLE BRAZILIAN POPULATIONS
Author
Elias, Maria Carolina
Slavov, Svetoslav Nanev
Lima, Alex Ranieri Jeronimo
Martins, Antonio Jorge
Barros, Claudia Renata Dos Santos
Moretti, Debora Botequio
Araujo, Eduardo L.
Marqueze, Elaine Cristina
Ribeiro, Gabriela
Ribeiro, Gabriela Mauric Frossard
Bernardino, Jardelina Souza Todao
Koser, Jaqueline Reginato
Clemente, Luan Gaspar
Crispin, Luiz Aurelio Campos
Alcantara, Luiz Carlos Junior
Coutinho, Luiz Lehmann
Giovanetti, Marta
Silva, Quetura Oliveira
Machado Neto, Raul
Haddad, Ricardo
Kashima, Simone
Viala, Vincent Louis
Covas, Dimas Tadeu
Sampaio, Sandra Coccuzzo
Slavov, Svetoslav Nanev
Lima, Alex Ranieri Jeronimo
Martins, Antonio Jorge
Barros, Claudia Renata Dos Santos
Moretti, Debora Botequio
Araujo, Eduardo L.
Marqueze, Elaine Cristina
Ribeiro, Gabriela
Ribeiro, Gabriela Mauric Frossard
Bernardino, Jardelina Souza Todao
Koser, Jaqueline Reginato
Clemente, Luan Gaspar
Crispin, Luiz Aurelio Campos
Alcantara, Luiz Carlos Junior
Coutinho, Luiz Lehmann
Giovanetti, Marta
Silva, Quetura Oliveira
Machado Neto, Raul
Haddad, Ricardo
Kashima, Simone
Viala, Vincent Louis
Covas, Dimas Tadeu
Sampaio, Sandra Coccuzzo
Affilliation
Instituto Butantan. São Paulo, SP, Brazil / Instituto Butantan. Center of Toxins, Immune Response and Cell Signaling. São Paulo, SP, Brazil.
University of São Paulo. Ribeirão Preto Medical School. Blood Center of Ribeirão Preto. Ribeirão Preto, SP, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Loccus. São Paulo, SP, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Universidade de São Paulo. Centro de Genomica Funcional. Piracicaba, São Paulo, Brasil.
Instituto Butantan. São Paulo, SP Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Universidade de São Paulo. Centro de Genomica Funcional. Piracicaba, São Paulo, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
University of São Paulo. Ribeirão Preto Medical School. Blood Center of Ribeirão Preto. Ribeirão Preto, SP, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
University of São Paulo. Ribeirão Preto Medical School. Blood Center of Ribeirão Preto. Ribeirão Preto, SP, Brazil / Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan, São Paulo, Brazil.
University of São Paulo. Ribeirão Preto Medical School. Blood Center of Ribeirão Preto. Ribeirão Preto, SP, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Loccus. São Paulo, SP, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Universidade de São Paulo. Centro de Genomica Funcional. Piracicaba, São Paulo, Brasil.
Instituto Butantan. São Paulo, SP Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Universidade de São Paulo. Centro de Genomica Funcional. Piracicaba, São Paulo, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan. São Paulo, SP Brazil.
University of São Paulo. Ribeirão Preto Medical School. Blood Center of Ribeirão Preto. Ribeirão Preto, SP, Brazil.
Instituto Butantan. São Paulo, SP Brazil.
University of São Paulo. Ribeirão Preto Medical School. Blood Center of Ribeirão Preto. Ribeirão Preto, SP, Brazil / Instituto Butantan. São Paulo, SP Brazil.
Instituto Butantan, São Paulo, Brazil.
Abstract
Background: Brazil has been dramatically hit by the SARS-CoV-2 pandemic and is a world leader in COVID-19 morbidity and mortality. Additionally, the largest country of Latin America has been a continuous source of SARS-CoV-2 variants and shows extraordinary variability of the pandemic strains probably related to the country´s outstanding position as a Latin American economical and transportation hub. Not all regions of the country show sufficient infrastructure for SARS-CoV-2 diagnosis and genotyping which can negatively impact the pandemic response.
Methods: Due to this reason and to disburden the diagnostic system of the inner São Paulo State, the Butantan Institute established the Mobile Laboratory (in Portuguese: LabMovel) for SARS-CoV-2 testing which started a trip of the most important "hotspots" of the most populous Brazilian region. The LabMovel initiated in two important cities of the State: Aparecida do Norte (an important religious center) and the Baixada Santista region which incorporates the port of Santos, the busiest in Latin America. The LabMovel was fully equipped with an automatized system for SARS-CoV-2 diagnosis and sequencing/genotyping. It also integrated the laboratory systems for patient records and results divulgation including in the Federal Brazilian Healthcare System.
Results: Currently,16,678 samples were tested, among them 1,217 from Aparecida and 4,564 from Baixada Santista. We tracked the delta introductio in the tested regions with its high diversification. The established mobile SARS-CoV-2 laboratory had a major impact on the Public Health System of the included cities including timely delivery of the results to the healthcare agents and the Federal Healthcare system, evaluation of the vaccination status of the positive individuals in the background of exponential vaccination process in Brazil and scientific and technological divulgation of the fieldwork to the most vulnerable populations.
Conclusions: The SARS-CoV-2 pandemic has demonstrated worldwide the importance of science to fight against this viral agent and the LabMovel shows that it is possible to integrate researchers, clinicians, healthcare workers and patients to take rapid actions that can in fact mitigate this and other epidemiological situations.
Share